Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters

Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
Nutrients ; 15(13)2023 Jun 21.
Article in English | MEDLINE | ID: mdl-37447152

ABSTRACT

Arachidonic acid (ARA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), which are long-chain polyunsaturated fatty acids (LCPUFAs), as well as lutein (L) and zeaxanthin (Z), can potentially improve brain function. However, the effect of a combination of these components (LCPUFAs + LZ) on memory function in healthy older individuals remains unclear. This study aimed to determine if LCPUFAs + LZ-supplemented food could improve memory function. Exploratory and confirmatory trials (Trials 1 and 2, respectively) were conducted in healthy older Japanese individuals with memory complaints. We conducted randomized, double-blind, placebo-controlled, parallel-group trials. Participants were randomly allocated to two groups: placebo or LCPUFAs + LZ. LCPUFAs + LZ participants were provided with supplements containing ARA, DHA, EPA, L, and Z for 24 weeks in Trial 1 and 12 weeks in Trial 2. Memory functions were evaluated using Cognitrax before and after each trial. Combined analyses were performed for subgroups of participants with cognitive decline in Trials 1 and 2. The results showed that supplementation with LCPUFAs + LZ did not significantly affect memory function in healthy, non-demented, older individuals with memory complaints whereas it improved memory function in healthy, non-demented, older individuals with cognitive decline.


Subject(s)
Fatty Acids, Omega-3 , Memory, Episodic , Humans , Aged , Lutein/pharmacology , Zeaxanthins/pharmacology , Docosahexaenoic Acids/pharmacology , Eicosapentaenoic Acid/pharmacology , Dietary Supplements , Fatty Acids , Arachidonic Acid/pharmacology , Double-Blind Method
2.
Sci Rep ; 10(1): 12906, 2020 07 31.
Article in English | MEDLINE | ID: mdl-32737350

ABSTRACT

Multifactorial lifestyle intervention is known to be more effective for ameliorating cognitive decline than single factor intervention; however, the effects of combining exercise with long-chain polyunsaturated fatty acids (LCPUFA) on the elderlies' cognitive function remain unclear. We conducted a randomised, single-masked placebo-controlled trial in non-demented elderly Japanese individuals. Participants were randomly allocated to the exercise with LCPUFA, placebo, or no exercise with placebo (control) groups. Participants in the exercise groups performed 150 min of exercise per week, comprised resistance and aerobic training, for 24 weeks with supplements of either LCPUFA (docosahexaenoic acid, 300 mg/day; eicosapentaenoic acid, 100 mg/day; arachidonic acid, 120 mg/day) or placebo. Cognitive functions were evaluated by neuropsychological tests prior to and following the intervention. The per-protocol set analysis (n = 76) revealed no significant differences between the exercise and the control groups in changes of neuropsychological tests. Subgroup analysis for participants with low skeletal muscle mass index (SMI) corresponding to sarcopenia cut-off value showed changes in selective attention, while working memory in the exercise with LCPUFA group was better than in the control group. These findings suggest that exercise with LCPUFA supplementation potentially improves attention and working memory in the elderly with low SMI.


Subject(s)
Aging , Cognition , Dietary Supplements , Exercise , Fatty Acids, Unsaturated/administration & dosage , Aged , Female , Humans , Male , Middle Aged
3.
J Alzheimers Dis ; 76(1): 387-398, 2020.
Article in English | MEDLINE | ID: mdl-32474473

ABSTRACT

BACKGROUND: Prevention of age-related cognitive decline and depression is becoming urgent because of rapid growing aging populations. Effects of vagal nerve activation on brain function by food ingredients are inadequately investigated; matured hop bitter acid (MHBA) administration reportedly improves cognitive function and depression via vagal nerve activation in model mice. OBJECTIVE: We investigated the effects of MHBA supplementation on cognitive function and mood state in healthy older adults with perceived subjective cognitive decline. METHODS: Using a randomized double-blind placebo-controlled trial design, 100 subjects (aged 45-69 years) were randomly assigned into placebo (n = 50) and MHBA (n = 50) groups, and received placebo or MHBA capsules daily for 12 weeks. RESULTS: Symbol Digit Modalities Test (SDMT) score assessing divided attention at week 12 was significantly higher (p = 0.045) and ß-endorphin at week 12 was significantly lower (p = 0.043) in the subjects receiving MHBA. Transthyretin in serum, a putative mild cognitive impairment marker, was significantly higher at week 12 in the MHBA group than in the placebo group (p = 0.048). Subgroup analysis classified by the subjective cognitive decline questionnaire revealed that in addition to improved SDMT scores, memory retrieval assessed using the standard verbal paired-associate learning tests and the Ray Verbal Learning Test at week 12 had significantly improved in the subgroup with perceived subjective cognitive decline and without requirement for medical assistance in the MHBA group compared with that in the placebo group. CONCLUSION: This study suggested that MHBA intake improves cognitive function, attention, and mood state in older adults.


Subject(s)
Affect/drug effects , Cognition/drug effects , Cognitive Dysfunction/drug therapy , Dietary Supplements , Humulus , Mental Status and Dementia Tests , Affect/physiology , Aged , Aging/drug effects , Aging/psychology , Cognition/physiology , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/psychology , Diagnostic Self Evaluation , Double-Blind Method , Female , Humans , Male , Middle Aged , Plant Extracts/administration & dosage , Plant Extracts/isolation & purification , Stress, Psychological/diagnosis , Stress, Psychological/drug therapy , Stress, Psychological/psychology
4.
Nutrients ; 10(7)2018 Jul 13.
Article in English | MEDLINE | ID: mdl-30011836

ABSTRACT

Background: Previous epidemiological and clinical studies have shown that dairy products have beneficial effects on cognitive decline and dementia. Enzymatic digestion of whey protein produces a whey peptide rich in tryptophan-tyrosine-related peptides which improve cognitive performance in mice. We evaluated the effects of whey peptides on cognitive functions in healthy adults in a randomized, double-blind, placebo-controlled design. Methods: 101 healthy adults (45 to 64 years), with a self-awareness of cognitive decline received either whey peptide or placebo supplements for 12 weeks. Changes in cognitive function were assessed using neuropsychological tests at 6 and 12 weeks after the start of supplementation. Results: Verbal fluency test (VFT) score changes tended to be higher in the whey peptide group compared with the placebo at 12 weeks. Subgroup analysis classified by the degree of subjective fatigue showed that changes in the VFT as well as the Stroop and subjective memory function tests between baseline and 6 weeks of intervention were significantly better in subjects with high-level fatigue from the whey peptide group as compared to the placebo group. CONCLUSIONS: Intake of whey peptide might improve cognitive function in healthy middle- and older-aged adults with high subjective fatigue levels. Further studies will elucidate the relationship among cognitive improvement, whey peptides, and psychological fatigue.


Subject(s)
Cognition/drug effects , Cognitive Dysfunction/diet therapy , Dietary Supplements , Mental Fatigue/diet therapy , Tryptophan/administration & dosage , Tyrosine/administration & dosage , Whey Proteins/administration & dosage , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/psychology , Double-Blind Method , Female , Healthy Volunteers , Humans , Japan , Male , Memory/drug effects , Mental Fatigue/diagnosis , Mental Fatigue/psychology , Middle Aged , Neuropsychological Tests , Time Factors , Treatment Outcome , Verbal Behavior/drug effects
5.
Nutr J ; 15: 25, 2016 Mar 09.
Article in English | MEDLINE | ID: mdl-26960416

ABSTRACT

BACKGROUND: Hops are the main components of beer that provide flavor and bitterness. Iso-α-acids, the bitter components of beer, have been reported to reduce body fat in humans, but the bitterness induced by effective doses of iso-α-acids precludes their acceptance as a nutrient. The matured hop bitter acids (MHBA) of oxidized hops appear to have a more pleasant bitterness compared to the sharper bitterness of iso-α-acids. While there has been little information concerning the identity of the MHBA compounds and their physiological effects, MHBA was recently found to be primarily composed of oxides derived from α-acids, and structurally similar to iso-α-acids. Here, we investigated the effects of matured hop extract (MHE) containing MHBA on reducing abdominal body fat in healthy subjects with a body mass index (BMI) of 25 to below 30 kg/m(2), classified as "obese level 1" in Japan or as "overweight" by the WHO. TRIAL DESIGN: A randomized, double-blind, placebo-controlled parallel group study. METHODS: Two hundred subjects (male and female aged 20 to below 65 years with a BMI of 25 or more and less than 30 kg/m(2)) were randomly assigned to two groups. During a 12-week ingestion period, the subjects in each group ingested daily 350 mL of test-beverage, either containing MHE (with 35 mg MHBA), i.e. the namely active beverage, or a placebo beverage without MHE. The primary endpoint was reduction of the abdominal fat area as determined by CT scanning after continual ingestion of MHE for 12 weeks. RESULTS: Compared to the placebo group, a significant reduction was observed in the visceral fat area after 8 and 12 w, and in the total fat area after 12 w in the active group. There was also a concomitant decrease in body fat ratio in the active group compared to the placebo group. No adverse events related to the test beverages or clinically relevant abnormal changes in the circulatory, blood and urine parameters were observed in either group. CONCLUSIONS: The present study suggests that continual ingestion of MHE safely reduces body fat, particularly the abdominal visceral fat of healthy overweight subjects. TRIAL REGISTRATION: UMIN-CTR UMIN000014185.


Subject(s)
Abdominal Fat/drug effects , Adiposity/drug effects , Humulus/chemistry , Overweight/drug therapy , Plant Extracts/administration & dosage , Adult , Aged , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Beer , Body Mass Index , Body Weight , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cyclohexenes/administration & dosage , Cyclohexenes/analysis , Dietary Carbohydrates/administration & dosage , Dietary Carbohydrates/analysis , Dietary Fats/administration & dosage , Dietary Fats/analysis , Dietary Fiber/administration & dosage , Dietary Fiber/analysis , Dietary Proteins/administration & dosage , Dietary Proteins/analysis , Double-Blind Method , Endpoint Determination , Energy Intake , Female , Humans , Male , Middle Aged , Motor Activity , Terpenes/administration & dosage , Terpenes/analysis , Triglycerides/blood , Waist Circumference , Young Adult
6.
Menopause ; 19(2): 202-10, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21934634

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the effects of the natural S-equol supplement on skin aging in equol-nonproducing Japanese postmenopausal women. METHODS: A randomized, double-blind, placebo-controlled trial examined the use of the natural S-equol supplement for 12 weeks in 101 postmenopausal Japanese women who were equol nonproducers. They were randomly assigned to one of three groups: placebo (n = 34), 10 mg S-equol/day (EQL10; n = 34), or 30 mg S-equol/day (EQL30; n = 33). Skin parameters of crow's-feet wrinkles (area and depth), hydration, transepidermal water loss, and elasticity were measured at baseline and at monthly intervals during treatment. Vaginal cytology, endometrial thickness, and mammography were performed before and after treatment. Serum hormone concentrations were measured at the same time as skin parameters. RESULTS: The EQL10 and EQL30 groups showed significant reductions in wrinkle area compared with the placebo group (P < 0.05). There was a significant difference in wrinkle depth between the placebo group and the EQL30 group (P < 0.05). Other skin parameters did not show significant differences after the treatment in any group. There were no abnormal results in hormone status or gynecological examinations. CONCLUSIONS: Our data suggest that natural S-equol supplementation (EQL10 and EQL30) may have a beneficial effect on crow's-feet wrinkles in postmenopausal women without serious adverse events.


Subject(s)
Equol/administration & dosage , Phytoestrogens/administration & dosage , Postmenopause/physiology , Skin Aging/drug effects , Dietary Supplements , Double-Blind Method , Equol/urine , Humans , Isoflavones/urine , Japan , Middle Aged , Pilot Projects , Placebos
SELECTION OF CITATIONS
SEARCH DETAIL